Company founded by Tsuyoshi Kurozumi and others as Koa Kagakukogyo Co., Ltd. (Katsushika-ku, Tokyo)
Launched manufacturing and sales of nutritional foods and medical supplies made with livestock organs as raw materials
Company name changed to Koa Eiyokagaku Kenkyusho Co., Ltd.
Exclusive distribution agreement and capital alliance executed with Tanabe Seiyaku Co., Ltd.
Company name changed to Nihon Eiyokagaku Co., Ltd.
Nihon Eiyokagaku NEK logo
Nihon Eiyokagaku carbon logo
Research laboratory interior
Research laboratory interior
Laboratory staff posed around Tsuyoshi Kurozumi, President
Launched sales of bacterial testing products
Powdered agar for the detection of bacteria (SS Agar "Eiken")
First company to succeed in creating a powdered agar for the detection of bacteria (isolation of typhoid and shigella bacteria), contributing to the development of communicable disease control and public health in Japan
First published "Modern Media," a clinical diagnostics academic information magazine
Modern Media August 1955 issue
Launched sales of bacterial drug sensitivity testing reagents (disk diffusion method)
Launched sales of tuberculosis culture medium "Ogawa Agar 'Eiken'"
Founded EIKEN KIZAI CO., LTD.
Completed new plant in Katsushika (Katsushika-ku, Tokyo: Katsushika Office)
Established the Clinical Diagnostics Division the following year and launched research and development of in vitro diagnostics
Opened Nihon Eiyokagaku Plant 1 and Plant 2
Launched sales of clinical chemistry reagents
"Alkaline Phosphatase Tube 'Eiken'"
Launched sales of urinalysis test reagents
"Uropaper A 'Eiken'" and "Uropaper B 'Eiken'"
Launched sales of immunological and serological reagents
Hemolytic streptococcal infection testing reagent "Streptolysin O 'Eiken'"
Completed phase-one construction of the Nogi Plant (Nogi, Tochigi: Nogi Division) and launched production
Completed Nogi Plant phase-one construction
Launched sales of blood culture medium bottles
"Culture Bottle No. 2"
Started the Saburo Kojima Memorial Society (business taken over by Kurozumi Medical Foundation (K M F) in 1993)
Launched sales of latex agglutination immunological and serological reagents
Rheumatoid factor measurement reagent "RA Reagent 'Eiken'"
Company name changed to Eiken Chemical Co., Ltd. on the 30th anniversary of its founding
Eiken Chemical Co., Ltd. company badge
Launched sales of "Pore Media" prepared culture medium
Completed Eiken Immunochemical Research Laboratory (Kita-ku, Tokyo: Oji Office) and launched operations
Eiken Immunochemical Research Laboratory
Launched sales of Radioimmunoassay (RIA) reagents
Launched sales of slide plate agglutination reagents using latex agglutination reaction
"Gestate Slide 'Eiken'"
Launched sales of bacterial identification reagents
Launched sales of the first immunological and serological reagents developed with a pioneering method that does not dilute the specimen
Completed new headquarters building (Bunkyo-ku, Tokyo) and launched operations
New headquarters building
Tsuyoshi Kurozumi, President, awarded the 4th Order of the Sacred Treasure for his achievements contributing to the improvement of health and hygiene both inside and outside of Japan
Launched sales of immunological and serological reagents using the SRID method
Opened the Toda Research Laboratory
Launched sales of reagents related to enzyme immunoassay methods (EIA method and ELISA method)
Launched sales of specialized reagents for use with fully-automated immunochemical analyzer using a latex agglutination reaction
Completed phase-one construction for the Nasu Plant (Otawara, Tochigi: Nasu Office) and launched production
Launched sales of urinary salt content measurement reagents
Launched sales of "KB Disk 'Eiken'" bacterial drug sensitivity testing reagents
Appointed Tadao Kurozumi as President and Representative Director
Tadao Kurozumi with Tsuyoshi
Launched sales of blood glucose self monitoring equipment and reagents
Launched sales of in vivo diagnostic contrast media
Launched sales of fecal immunochemical test reagents
Launched sales of the "BACTSYSTEM" bacterial data management system
Opened resident office in San Diego, USA
Launched sales of bacterial drug sensitivity testing reagents (fluid culture dilution method)
Launched distribution of Tosoh Corporation enzyme immunoassay equipment (AIA) and dedicated reagents
Launched sales of the world's first fully-automated fecal occult blood analyzer and dedicated reagents
Listed stock in the Second Section of the Tokyo Stock Exchange
January 29, 1990 Nihon Keizai Shimbun
Launched sales of "Uropaper GP 'Eiken'" OTC urinalysis test strip
Completed Biochemical Research Laboratory (Nogi, Tochigi) and launched operations
Biochemical Research Laboratory
Launched sales of automated urine analyzer
Closed Katsushika Office and Toda Research Laboratory
Established the Kurozumi Medical Foundation (K M F), presented first research grants
Launched sales of "LZ Series" reagents for clinical chemistry analyzers using the latex agglutination reaction
Launched sales of "Lumispot AL-1000" chemiluminescent immunoassay analyzer and dedicated reagents
Began overseas expansion of fecal immunochemical test reagents and analyzer business
Launched sales of fecal immunochemical test reagents for manual
Launched sales of "US-3100" and "US-3200" fully-automated urine analyzer and "Uropaper α II 'Eiken'" dedicated reagents
Announced development of LAMP method new gene amplification technology
Launched sales of "US-2100R" automated urine analyzer
Launched sales of "OC-SENSOR μ(Micro)" fully-automated fecal occult blood analyzer
Terminated sales agreement with Tanabe Seiyaku, began in-house sales of in vitro diagnostics and equipment (terminated capital alliance in 2007)
Launched sales of "OC-SENSOR neo" fully-automated fecal occult blood analyzer
Launched sales of "US-3100R" fully-automated urine analyzer
Selected as one of the specified brands of the Tokyo Stock Exchange First Section
Launched sales of "Loopamp Series" genetic testing reagents and measurement equipment utilizing LAMP
"Loopamp Bovine Embryo Sexing Kit"
Launched sales of for LAMP-based in vitro diagnostics
"Loopamp SARS-CoV detection kit"
Established EIKEN SHANGHAI CO., LTD. (currently EIKEN CHINA CO., LTD.)
EIKEN SHANGHAI CO., LTD.
Acquired ISO13485 and ISO9001 certifications
Executed a joint development contract with FIND for a rapid genetic tuberculosis detection method based on the LAMP method
Launched sales of "US-1000" automated urine analyzer
Executed a business partnership agreement and capital alliance with Otsuka Pharmaceutical Co., Ltd.
Launched sales of "Dry Plate 'Eiken' 192" bacterial drug sensitivity testing reagent plates
"Dry Plate 'Eiken' 192" plates
Participated in planning for the BRAVE CIRCLE campaign to eradicate colorectal cancer
Launched sales of "OC-SENSOR DIANA" fully-automated fecal occult blood analyzer
Merged with EIKEN KIZAI CO., LTD., previously a subsidiary
Launched sales of "US-3300" fully-automated urine analyzer
Appointed Tetsuya Teramoto as President and CEO
Relocated headquarters and integrated three Tokyo offices (Taito-ku, Tokyo)
Successfully developed the procedure for ultra rapid extraction method (PURE method) for use with the LAMP method
Launched sales of "US-2200" automated urine analyzer
Launched sales of "US-3100Rplus" fully-automated urine analyzer
Launched sales of "LoopampEXIA (LA-500)" real-time turbidimeter for LAMP
Launched sales of "OC-SENSOR io" fully-automated fecal occult blood analyzer
Acquired ISO14001 certification
Established Europe office in Amsterdam, Holland
Completed Operation Management Center (OMC Building) at the Nogi Division and launched operations
Launched sales of "Immunocatch Series" rapid diagnostics test kits
Launched sales of fully-automated bioluminescent enzyme immunoassay analyzer and dedicated reagents
Appointed Morifumi Wada as President and CEO
Launched sales of "OC-SENSOR PLEDIA" fully-automated fecal occult blood analyzer
Began development of compact, next-generation fully-automated genetic testing equipment and multi-item testing chips utilizing LAMP
Launched sales of "US-3500" fully-automated urine analyzer
Formed a tie-up with Sysmex Corporation for the urine chemistry testing business in overseas markets
LAMP-based tuberculosis molecular diagnostics (TB-LAMP) recommended by WHO
Executed global distribution contracts for tuberculosis and malaria genetic diagnostic reagents and equipment use of the LAMP method through agreement with HUMAN, Germany
Completed Dried Product Plant (DPP Building) at the Nogi Division, established an expanded production line for urinalysis test strips
Launched sales of "US-1200" automated urine analyzer
Conducted preparations for expanding the Nogi Division
"Modern Media" academic information magazine reached 750 volumes